Loading...
Found 147 results for Neoplasm
A listing of Neoplasm medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
S
Scott Goebel, MD
What is the purpose of this study?Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with theyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in inhildren, adolescents and young adults with refractory ADV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) ord organ …
A Phase II trial Evaluating Safety and Efficacy of Epcoritamab with Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
V
Varun Mittal
The goal of this study:Estimate complete remission (CR) rate per the Lugano classification with a combination of epcoritamab and GDP in subjects with relapsed large cell lymphoma.Estimate overall response rate (ORR) per the Lugano classification with a combination of epcoritamab and GDP in subjects with relapsed large cell lymphoma.Estimate duration …
National Liver Cancer Screening Trial (TRACER)
N
Naga Chalasani, MD
What is this study about?The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection. Eligible patients will be randomized in a 1:1 fashion to Arm A using …
Detection of late subclinical cardiovascular disease in testicular cancer survivors exposed to cisplatin chemotherapy and bone marrow transplant
N
Nabil Adra, MD
Testicular cancer (TC) is diagnosed in young adult males between ages 18-39 and TC treatment involves the use of platinum therapy (CBCT) which can have long-term cardiovascular effects. We are looking at cholesterol and hormone changes, as well as blood vessel changes for coronary artery disease or blockages in the …
Hpc Offered for Preserve Expansion
J
Jodi Skiles
Ossium produces cryopreserved hematopoietic progenitor cell bone marrow (HPC, Marrow (Cryopreserved)) recovered from deceased organ donors using good manufacturing practice (GMP) processing, Ossium’s HPC, Marrow (Cryopreserved) is supplied in units suitable for transplantation by infusion, the same procedure used for transplantation of other sources of HPCs, such as live donor …
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
S
Scott Coven
This phase I trial studies the side effects and best dose of trametinib and everolimus ing pediatric and young adult patients with gliomas that have come back (recurrent). Trametinib acts by targeting a protein in cells called MEK and disrupting tumor growth.verolimus is a drug that may block another pathway …
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
J
Jenny Belsky, DO
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most …
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
A
Anthony Ross
This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after previous treatment, or does not respond to therapy (refractory). Langerhans cell histiocytosis is a …
A Phase 1b/2 Trial of Targeted Immunotherapy with Daratumumab Following Myeloablative Total Body Irradiation (TBI)-Based Conditioning and Allogeneic Hematopoietic Cell Transplantation in Children, Adolescents and Young Adults with High-Risk T-Cell Acute Lymphoblastic Leukemia and Lymphoma
J
Jodi Skiles
A Phase 1b/2 trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA) with high risk T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy). THIS STUDY IS …
Testing the Addition of the Anti-Cancer Drug Venetoclax And/Or the Anti-Cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed Kmt2A-Rearranged or Kmt2A-Non-Rearranged Leukemia
A
Amanda J. Saraf, DO
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged [R]) or without a KMT2A gene rearrangement (KMT2A-germline [G]). Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) …
Please choose between Voice or SMS based delivery of verification code
or